20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MoonLake Immunotherapeutics (MLTX) operates in the BIOTECHNOLOGY industry and is headquartered in Zug, Switzerland with about 130 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, MLTX reported $0M in revenue and ($227M) in net income.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — | — |
| Gross Profit | — | ($3M) | ($1M) | $0M | $0M | $0M | — |
| Gross Margin % | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($268M) | ($245M) | ($143M) | ($54M) | ($65M) | ($5M) | $0M |
| Operating Margin % | — | — | — | — | — | — | — |
| Net Income | ($264M) | ($227M) | ($119M) | ($36M) | ($65M) | ($5M) | $0M |
| Net Margin % | — | — | — | — | — | — | — |
| EBITDA | ($251M) | ($220M) | ($120M) | ($44M) | ($65M) | ($5M) | $0M |
| Earnings Per Share (EPS) | $-3.88 | $-3.53 | $-1.89 | $-0.73 | $-2.20 | $-0.12 | $-0.01 |
| Shares Outstanding (M) | 74M | 64M | 63M | 49M | 29M | 37M | 15M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | ($1M) | ($1M) | ($1M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($62M) | ($70M) | ($65M) | ($71M) | ($61M) | ($47M) | ($50M) | ($43M) |
| Operating Margin % | — | — | — | — | — | — | -48679.8% | — |
| Net Income | ($62M) | ($70M) | ($62M) | ($70M) | ($55M) | ($40M) | ($46M) | ($35M) |
| Net Margin % | — | — | — | — | — | — | -44776.2% | — |
| EBITDA | ($58M) | ($66M) | ($60M) | ($67M) | ($53M) | ($40M) | ($45M) | ($36M) |
| Earnings Per Share (EPS) | $-0.84 | $-0.98 | $-0.97 | $-1.10 | $-0.87 | $-0.63 | $-0.72 | $-0.56 |
| Shares Outstanding (M) | 74M | 71M | 64M | 63M | 63M | 63M | 63M | 63M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($225M) | ($196M) | ($117M) | ($43M) | ($56M) | ($35M) | $0M |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($225M) | ($196M) | ($117M) | ($43M) | ($56M) | ($35M) | $0M |
| FCF Margin % | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($56M) | ($66M) | ($59M) | ($45M) | ($55M) | ($38M) | ($48M) | ($25M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($56M) | ($66M) | ($59M) | ($45M) | ($55M) | ($38M) | ($49M) | ($25M) |
| FCF Margin % | — | — | — | — | — | — | -47765.6% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Assets | $574M | $424M | $478M | $527M | $77M | $10M | $117M |
| Cash & Cash Equivalents | $478M | $335M | $180M | $451M | $40M | $8M | $1M |
| Total Liabilities | $146M | $120M | $25M | $13M | $8M | $21M | $4M |
| Total Debt (Short + Long-Term) | $101M | $75M | $1M | $1M | $0M | $15M | $0M |
| Total Shareholders' Equity | $428M | $304M | $447M | $496M | $49M | ($12M) | $112M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MLTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms